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EFFECTIVENESS AND COST-EFFECTIVENESS OF A GROUP-BASED PAIN
SELF-MANAGEMENT INTERVENTION FOR PATIENTS UNDERGOING
TOTAL HIP REPLACEMENT: FEASIBILITY STUDY FOR A
RANDOMISED CONTROLLED TRIAL
V. Wylde, E. Marques, N. Artz, A. Blom, R. Gooberman-Hill. Univ. of
Bristol, Bristol, United Kingdom
Purpose: Total hip replacement (THR) is a common elective surgical
procedure and can be effective for reducing chronic pain. However,
waiting times for THR can be considerable, and patients often experi-
ence signiﬁcant pain during this time. A pain self-management inter-
vention may provide patients with the skills to enable them to manage
their pain and its impact more effectively during the wait for surgery.
However, studies of arthritis self-management programmes have faced
challenges because of low recruitment rates, poor intervention uptake,
and high attrition rates. Therefore, this study aimed to evaluate the
feasibility of a randomised controlled trial (RCT) to assess the effec-
tiveness and cost-effectiveness of a group-based pain self-management
course for patients undergoing THR and assess the acceptability of the
intervention. Speciﬁc objectives were to assess trial design, ascertain
recruitment and retention rates, identify barriers to participation, reﬁne
data collection methods, and evaluate uptake and patient satisfaction
with the course.
Methods: Patients listed for a THR at the Avon Orthopaedic Centre in
Bristol were sent a postal invitation about the study. After recruitment,
participants were randomised to attend a pain self-management course
plus standard care or standard care only using a computer-generated
randomisation system (Minim). The pain self-management course was
delivered by Arthritis Care and consisted of two half-day group sessions
prior to surgery and one full-day group session 2-4 months after sur-
gery. A structured course evaluation questionnaire was completed by
participants after the sessions. Outcomes assessment was by postal
questionnaire prior to surgery and 1-month, 3-months and 6-months
after surgery. Self-report resource use data were collected using a diary
prior to surgery and inclusion of resource use questions in the 3-month
and 6-month post-operative questionnaires. Brief telephone interviews
were conducted with consenting non-participants to explore barriers to
participation. NHS ethics approval was obtained (11/SW/0056) and
participants provided informed, written consent.
Results: Postal invitations were sent to 385 eligible patients and 88
patients consented to participate (23% recruitment rate). Participants
had a mean age of 66 years and 65% were female. Brief interviews with
57 non-participants revealed the most common reasons for non-par-
ticipation were perceptions about the intervention and difﬁculties in
getting to the hospital to attend the course. Of the 43 patients rando-
mised to the intervention group, 28 attended the pre-operative pain
self-management sessions and 11 attended the post-operative sessions.
Participant satisfaction with the course was high, and patients enjoyed
the group format of the course.Retention of participants was acceptable,
with 83% completing follow-up. Questionnaire return rates were high at
all assessment times (76-93%), with the exception of the pre-operative
resource use diary (35%). Completion rates for the resource use ques-
tions varied by category and allowed for an economic perspective from
the health and social care payer to be taken.
Conclusion: Undertaking feasibility work for a RCT is labour-intensive;
however this study highlights the importance of conducting such work.
Postal recruitment resulted in a low recruitment rate and brief inter-
views with non-participants provided valuable information on barriers
to participation. Embedding collection of resource use data within
questionnaires resulted in higher completion rates than using resource
use diaries. While patients who attended the course gave positive
feedback, attendance was low. Findings from this feasibility study
enable us to design successful deﬁnitive group-based RCTs in the future,
ensuring the delivery of effectiveness and cost-effectiveness evidence
to inform service provision for patients undergoing THR.761
CAPSAICIN TREATMENT FOR OSTEOARTHRITIS PAIN: A META-
ANALYSIS
L. Laslett, G. Jones. Univ. of Tasmania, HOBART, Australia
Background: Capsaicin appears to be effective for osteoarthritis pain
but it is uncertain whether the effect has a dose response, is consistent
across joints, or changes over time.
Purpose: To perform a quantitative overview the use of topical cap-
saicin in the therapy of painful osteoarthritis (OA) in adults, and to
assess whether effects vary by formulation strength, joint site, or
treatment duration.
Methods: Literature databases (PubMed, EMBASE, ISI Web of Knowl-
edge) were searched for randomized controlled trials for use of topical
capsaicin (or capsaicin-like therapies) in OA using the keywords:
“capsaicin”, “osteoarthritis” “double-blind method”, “randomized con-
trolled trial [publication type]” or “controlled clinical trial [publication
type]” up to 2012. Studies not in English were excluded. Trials were
compared for pain scores (assessed using visual analog scales (VAS)),
patient global evaluation of treatment effectiveness and application site
burning using standardised mean differences (SMD), using RevMan.
Results: Five double-blind randomized controlled trials and one case-
crossover trial were identiﬁed, testing topical capsaicin four times daily.
Formulations ranged from 0.025% - 0.075%, and trial durations from 4-
12 weeks. Trials assessed OA of the knee (n¼ 3), hand (n¼ 1), and a mix
of joints (n ¼ 2). Patients were typically required to have at least
moderate pain and either radiologically or clinically deﬁned OA, or both.
Treatment efﬁcacy of capsaicin (compared to placebo) for change in VAS
pain score was moderate, at 0.44 (95% CI 0.25-0.62) over 4 weeks of
treatment. There was no heterogeneity between studies, indicating no
between-study differences, including effect of OA site or treatment
concentration. There was disagreement on effectiveness over time. Two
studies reported treatment beyond 4 weeks, with the ﬁrst study
reporting an effect size of -9mm after 12 weeks, with the maximum
difference between groups occurring at 4 weeks. The second study
reported that between-group differences increased over time, up to 20
weeks.
Capsaicin was reported as being safe and well-tolerated, with no sys-
temic toxicity. The most common side effect reported was mild appli-
cation site burning, affecting 35-100% of capsaicin-treated patients; the
risk ratio was 4.22 (95% CI 3.25-5.48), reported in 5 trials. Incidence of
burning peaked in week 1, with incidence rates declining over time,
plateauing from weeks 2-12.
Conclusions: Topical capsaicin treatment four times daily is moderately
effective in reducing pain intensity up to 20 weeks regardless of site of
application anddose inpatientswith at leastmoderatepain and clinical or
radiologically deﬁned OA. Capsaicin treatment is also generally well tol-
erated, suggesting that capsaicin should be used early in theOA treatment
algorithm, especially for superﬁcial joints such as the hand and knee.
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EFFECT OF TISSUEGENE-C, A NOVEL CELL AND GENE THERAPY, ON
PAIN AND CARTILAGE REGENERATION IN A RAT OSTEOARTHRITIS
MODEL
B. Lee, K. Choi, H. Lee, D-W. Lee, H. Lee, H. Choi, S. Kim. Kolon Life Sci.,
Inc., Gwacheon-si, Republic of Korea
Purpose: TissueGene-C(TG-C) has been developed as a cell and gene
therapy for patients withosteoarthritis. It is a mixture of non-trans-
duced human chondrocytes (hChonJ) and genetically modiﬁed chon-
drocytes expressing TGF-b1 (hChonJb#7). Phase 2b clinical trials have
shown that TG-C signiﬁcantly improved IKDC and 100 mm VAS scores
over placebo when administered to the knee joints of osteoarthritic
patients. In this study, a rat model of osteoarthritis was used to identify
the role of individual components of TG-C.
Methods: A rat model of osteoarthritis was induced by injection of
monosodium iodoacetate (MIA) into the left knee joint, which resulted
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pain-related behaviors were selected for the evaluation of TG-C for its
individual cell type (1. hChonJ; 2. hChonJb#7; or 3. TG-C (hChonJ and
hChonJb#7)) for pain and cartilage regeneration. At twoweekspost MIA
administration, the individual cells were injected into the osteoarthritic
knee cavity. The effect of the cells on the mechanical allodynia was
evaluated by von Frey ﬁlament test in blinded fashion. After completing
the test, the knees were harvested for histological analysis.
Results: In MIA model, the reduction of pain was observed in hChonJ#7
treated and TG-C treated groups from day 15 post injection but not in
hChonJ alone or in untreated group. The magnitude of pain reduction in
hChonJ#7 treated group was comparable to that of TG-C treated group
up to day 28. However, TG-C showed longer and greater pain reduction
thereafter up to 8 weeks, indicating synergy between hChonJ and
hChonJ#7 cells. The histological analysis showed that the integrity of
cartilage was severely damaged by MIA treatment. However, hChonJ#7
cell treatment improved the damaged cartilage, in addition, TG-C
treatment showed even greater improvement in the regeneration of the
cartilage.
Conclusions: This study showed that TG-C treatment could reduce pain
and regenerate damaged cartilage in a rat MIA osteoarthritis model and
contributes to the understanding of the effect of TG-C on the
improvement of clinical outcomes observed in phase 2b trials.
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TRADITIONAL CHINESE HERBAL MEDICATED BATH THERAPIES FOR
OSTEOARTHRITIS
B. Chen y, M. Chung z, H. Zhan y, Y. Cao y, C. Wang z. y Shuguang Hosp.
Afﬁliated to Shanghai Univ. of Traditional Chinese Med., Shanghai,
China; z Tufts Med. Ctr., Boston, MA, USATable 1
Effect of traditional Chinese herbal medicated bath therapy on knee osteoarthritis
Author year Na Ageb Bath therapy (formula, water
temperature, dose)c
Control intervention
Li, 2011 204 63 14 Herbs: 9-30g each, 30 min,
twice a day.
Loxoprofen, 60 mg,
3/day
Zhang, 2012 96 58 14 Herbs: 6-15g each, 30 min,
twice a day, Hyaluronate
injection, 2ml/wk
Hyaluronate injectio
12ml/1 wk
Du, 2012 60 63 9 Herbs: 12-15g each, 40-45C,
20-30 min, 2x/day.
Diclofenac topical c
2#/ day.
Chen, 2013 60 57 10 Herbs: 5-30g each, 35-60C,
30 min, 1-2x/day
Diclofenac diethylam
2#/day
Zhang, 2011 90 58 8 Herbs: 5-15g each, 20 min,
once or twice a day
Diclofenac sodium,
75 mg/day
Wu, 2011 98 55 8 Herbs: 20g each, 40 min,
every other day Acupuncture.
Meloxicam, 7.5 mg/
Huang, 2011 120 58 31 Herbs: 9-18g each, 20 min,
twice a day. Oral herbal
medicine
Hyaluronate injecti
12ml/wk
Cheng, 2012 78 53 16 Herbs: 10-30g each, 30 min,
twice a day. Oral herbal
medicine
Meloxicam,
50 mg2/day
Zhang, 2012 60 63 14 Herbs: 10-30g each,
twice a day
Hyaluronate injecti
12ml/wk
Xu, 2013 90 70 13 Herbs: 10-30g each, 40C,
10 min, 3 -4 times/day,
Hyaluronate injection,
12ml/1 wk
Hyaluronate injectio
12ml/1 wk
Wei, 2013 90 62 7 Herbs: 10g each, 30 min, once
a day, Ibuprofen, 1#/day
Ibuprofen, 1#/day
Zhen, 2010 108 60 12 Herbs; 10-30g each, 30 min
twice a day
Diclofenac sodium,
50 mg, 2#/day
a N ¼ number of patients included.
b Age reported in years as a mean.
c Main ingredients:: Lycopodium Clavatum, Garden Balsam Stem, Carthamus Tinctorious,
Zanthoxyli. Additional ingredients: Chinese Starjasmine Stem, Asarum Sieboldii, Erythrin
d Between group comparison.Purpose: Traditional Chinese Herbal Medicated Bath Therapies are
considered to have anti-inﬂammatory effects, activate blood circulation
to remove blood stasis and improve “hemorheologicals” for arthritis. A
comprehensive review of the literature is an important step for
understanding its beneﬁts for knee osteoarthritis (KOA). We system-
atically reviewed the literature on the effects of Herbal Medicated-bath
Therapies in patients with KOA.
Methods: We performed a comprehensive search of three universal
Chinese databases and reference lists of published articles through
November 2013. We included only randomized controlled trials (RCTs)
using herbal medicated bath therapy for adult patients with KOA. The
effect of the Herbal Medicated-Bath Therapy on clinical symptoms was
measured with WOMAC, visual analogue scale, Japanese Orthopedic
Association score, and Lysholm’s score. We accepted the composite
outcome criteria developed by the Chinese National Institute of Rheu-
matology as an endpoint. Study quality was assessed with Jadad criteria
assessing randomization, single blinding, and dropout rates for each
study. The differences between treatment groups were reported as
mean change (P-value).
Results:We identiﬁed 40 potentially relevant studies. Twelve RCTs with
a total of 1154 subjects (62% female) met eligibility criteria. Table 1
summarizes the trials evaluating the effect of Herbal Medicated Bath
Therapies on symptom improvement. Mean age was 60 years and mean
symptom duration was 157 months. All studies were conducted and
published in China between 2010 and 2013, Average bath formula in the
treatment groups included 13 Chinese herbs, vaporing and washing
around the knee with temperature in range 35-600C, 20-40 minutes,
once or twice a day. Mean treatment duration was 3.4 weeks (range 2-
5), for 1-3 courses. All control groups used oral nonsteroidal anti-
inﬂammatory analgesics or intra-articular Hyaluronate injection. Two
studies also used additional oral Chinese herbs. The overall quality ofDuration
(wks)
Outcome
measures
Effect on symptom
(mean or percentage
improvement)d
P value
4 VAS Pain 0.7 Y < 0.05
n, 5 Lysholm''s score 8.4 [ < 0.01
ream, 4 WOMAC pain 0.7Y 0.06
ine, 4 WOMAC pain 5.3 Y < 0.05
2 Lysholm''s score Treatment effect [
87% vs. 67%
< 0.01
day 4 Chinese composite
outcome
Treatment effect [
93% vs. 65%
< 0.05
on, 4 Japanese Orthopaedic
Association criteria
Treatment effect: [
97% vs. 79%
< 0.05
3 Chinese Orthopaedic
Functional Outcome
-1.7
(lower score ¼ better
outcome)
< 0.05
on, 4 Chinese composite
outcome
Treatment effect [
77% vs. 67%
< 0.01
n, 5 Chinese composite
outcome
Treatment effect [
91% vs. 69%
< 0.01
2 Chinese composite
outcome
Treatment effect [
93% vs. 87%
< 0.05
4 Chinese composite
outcome for pain
Treatment effect: [
84% vs. 65%
< 0.05
Processed Radix Aconiti, Kusnezoff Monkshood Root, Radix Clematidis, Pericarpium
a Indicalam, Achyranthes Bidentata, Chinese Quince.
